危重急性肾损伤患者的β-内酰胺类剂量下调:范围综述
本范围综述遵循PRISMA-ScR指南,检索Medline、Embase、Web of Science、Cochrane CENTRAL和Google Scholar(建库至2025年3月24日),纳入危重成人急性肾损伤接受β-内酰胺类治疗并报告临床或药理学结局的研究。共筛查1436篇文献,纳入11项研究、1407例患者,多数研究偏倚风险高,仅1项为随机对照试验。7项研究报告血药浓度,急性肾损伤患者浓度普遍偏高,即使剂量已下调;1项研究显示早期剂量下调与神经毒性发生率降低相关,1项研究报告早期下调与治疗失败率升高相关,3项研究将延迟下调与死亡率降低相联系。结论认为当前证据有限且质量低,延迟下调可能改善临床结局,但亟需进一步前瞻性研究。
要点
- 纳入11项研究、1407例危重成人急性肾损伤患者,多数为观察性研究,仅1项随机对照试验,偏倚风险高。
- 7项研究报告β-内酰胺类血药浓度,急性肾损伤患者浓度普遍偏高,即使剂量已下调。
- 1项研究显示早期剂量下调与神经毒性发生率降低相关。
- 1项研究报告早期剂量下调与治疗失败率升高相关。
- 3项研究将延迟剂量下调与死亡率降低相联系。
适用人群与场景
- 危重成人急性肾损伤患者,接受β-内酰胺类抗生素治疗,报告临床或药理学结局。
研究设计与关键结果
- 研究类型为范围综述,遵循PRISMA-ScR指南,检索Medline、Embase、Web of Science、Cochrane CENTRAL和Google Scholar(建库至2025年3月24日),纳入11项研究、1407例患者,多数为观察性研究,1项为随机对照试验,多数研究偏倚风险高。
- 7项研究报告β-内酰胺类血药浓度,急性肾损伤患者浓度普遍偏高,即使剂量已下调。
- 1项研究显示早期剂量下调与神经毒性发生率降低相关。
- 1项研究报告早期剂量下调与治疗失败率升高相关。
- 3项研究将延迟剂量下调与死亡率降低相联系。
证据类型、等级与局限
- 证据类型:范围综述,纳入11项研究(多数观察性研究,1项随机对照试验),多数研究偏倚风险高;使用ROB-2和ROBINS-E工具评估研究质量。
- 局限:当前证据有限且质量低;进一步按抗生素类型或患者特征分层不可行;方案未前瞻性注册。
对床旁实践的改变
- 作者认为延迟剂量下调可能改善临床结局,但证据有限且质量低,亟需进一步前瞻性研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Acute kidney injury is a common complication in critically ill patients, often coinciding with the need for antibiotic therapy. The dose of beta-lactam antibiotics is frequently adjusted and often reduced based on estimated Glomerular Filtration Rate. However, early dose reductions may lead to underdosing, especially during the critical first 48 h of infection treatment, when acute kidney injury may be transient and adequate antibiotic treatment is critical. While some reviews suggest delaying dose reductions improves clinical outcomes, evidence remains limited. This scoping review evaluates the current literature on beta-lactam dosing strategies in critically ill patients with acute kidney injury, focusing on pharmacological and clinical outcomes.
METHODS: We conducted a systematic scoping review following PRISMA-ScR guidelines. We searched Medline, Embase, Web of Science, Cochrane CENTRAL, and Google Scholar from database inception through March 24, 2025. Two reviewers independently screened all articles and assessed study quality using ROB-2 and ROBINS-E tools. Eligible studies included critically ill adult patients with acute kidney injury, receiving beta-lactams, and reporting clinical or pharmacological outcomes. Data were extracted using a standardized template and categorized by pharmacological or clinical outcomes. Further stratification by antibiotic type or patient characteristics was not feasible.
RESULTS: Out of the 1,436 screened articles, 11 studies involving 1,407 patients were included. The risk of bias was high in most studies. Most studies were observational; one was a randomized controlled trial. Seven studies reported beta-lactam plasma concentrations. Higher concentrations were generally observed in patients with acute kidney injury, even though dosages were oftentimes already reduced. One study associated early dose reductions with lower rates of neurotoxicity. One study reported higher rates of treatment failure with early dose reductions and three studies linked delayed dose reductions to reduced mortality.
CONCLUSIONS: Current evidence on beta-lactam dose reduction in critically ill patients with acute kidney injury is limited and of low quality. Delaying reductions may improve clinical outcomes, but further prospective studies are urgently needed.
TRIAL REGISTRATION: The protocol for this scoping review was not prospectively registered.
参考来源
- Horstink MMB, Rietdijk WJR, Geel DR, et al. Beta-lactam dose reductions in critically ill patients with acute kidney injury: a scoping review. Crit Care. 2025. PMID: 41331481. doi:10.1186/s13054-025-05736-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。